IMPORTANCE Registry data show that maternal panic disorder, or anxiety disorders in general, increase the risk for adverse pregnancy outcomes. However, diagnoses from registries may be imprecise and may not consider potential confounding factors, such as treatment with medication and maternal substance use.
D uring pregnancy, up to 5% of women have panic disorder and as many as 10% have generalized anxiety disorder (GAD).
1 Although the impact of a maternal major depressive episode (MDE) has been explored extensively with regard to adverse birth outcomes, 2 attention devoted to anxiety disorders has been sparse. Several population-based registry studies show associations between panic disorder and adverse birth outcomes, such as delivery of a small for gestational age 3 or preterm infant. 3, 4 A small study found that pregnant women with panic disorder had smaller babies and shorter gestations than women without either any psychiatric illness or GAD specifically.
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The presence of any anxiety disorder, as determined by medical record review, has also been linked to risk of preterm birth and delivery by cesarean section. 6 The investigations reported above have not considered possible confounding effects from maternal medication use and other factors. Serotonin reuptake inhibitors (SRIs), which are used to treat panic disorder and GAD in pregnancy, are associated with some adverse birth outcomes. A previous study showed that neonates exposed to an SRI in pregnancy are more likely to be born preterm than are unexposed neonates, 7 a finding in line with most research, 8, 9 including work that used rigorous methods to control for confounding. 10 Use of an SRI in pregnancy has also been associated with delivery of a low-birth-weight baby in some 11, 12 but not all 13,14 studies. Mild and time-limited respiratory problems have also been found in neonates exposed to SRIs in utero. 15 Maternal complications linked with SRI use include gestational hypertension, [16] [17] [18] preeclampsia, 12, 18, 19 and cesarean delivery. 20, 21 Benzodiazepines, also used to treat anxiety disorders, can confound associations between birth outcomes and SRI use 22 or anxiety disorders. They have been implicated in the risk of preterm birth, 22-25 delivery of a low-birth-weight infant, 25 and neonatal respiratory distress. 22, 25 In this report, we extend prior work 7, 26 and specifically probe the association between exposures of panic disorder, GAD that endured 1 month rather than 6 months, SRI and benzodiazepine treatment, and a broader array of outcomes that include several maternal and neonatal pregnancy complications, including (1) hypertensive diseases of pregnancy (gestational hypertension or preeclampsia), (2) cesarean delivery, (3) preterm birth, (4) delivery of a lowbirth-weight infant, (5) minor neonatal respiratory interventions, and (6) neonatal ventilatory support. We included interactions between an MDE and anxiety disorders given a prior finding that an MDE moderates the effect of posttraumatic stress disorder (PTSD) on the risk of preterm birth. 26 We hypothesized that panic disorder but not GAD would increase the risk of preterm or low-birth-weight delivery. We also hypothesized that benzodiazepine use would increase the risk of preterm birth, cesarean delivery, and the use of neonatal ventilatory support, and that SRI use would be associated with cesarean delivery and hypertensive diseases of pregnancy. A previous study showed an association between SRI use and preterm birth.
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Methods

Study Design
Details of the study have been reported. 7 Briefly, this was a cohort study conducted between July 1, 2005, and July 14, 2009, at the Yale University School of Medicine, New Haven, Connecticut, and 137 collaborating hospitals and private practices throughout Connecticut and southern Massachusetts. All delivery hospitals provided human participants approval; a complete list is given in the eAppendix in the Supplement.In addition, participants provided verbal consent for screening and written consent for interviews.
Inclusion and Exclusion Criteria
Women were eligible if they were at least 18 years of age and
had not yet reached 17 weeks of pregnancy. They were ineligible if they had a known multifetal pregnancy, were receiving insulin treatment for diabetes, did not speak English or Spanish, did not have access to a telephone, or had plans to relocate or voluntarily terminate their pregnancy.
Recruitment and Assessment Procedures
The aim of the parent study was to assess birth outcomes among women with an MDE or a trauma history or who were undergoing antidepressant treatment. Women were given a letter at their usual obstetrical visit and invited to participate in a study of pregnancy and health. Possible participants provided a signature and telephone number, and study staff called possible participants and screened them for an MDE or trauma or use of antidepressant agents. All women who screened positive for these exposures during a telephone interview were offered participation. We also included a randomly selected nonexposed comparison group. After screening, participants were interviewed at home prior to 17 weeks of pregnancy and reinterviewed by telephone at 28 (±2) weeks' gestation and again 8 (±4) weeks after delivery. Women with a psychiatric condition who were not receiving care were offered treatment referrals or, if there was a question of safety, we emergently conducted a psychiatric assessment.
Interviewers received a minimum of 4 days of training in the administration of the interview and completed at least 6 practice interviews and 4 supervised interviews. Interviews were taped and a subset was reviewed for quality control.
Exposure and Outcome Measures
At each interview, we administered the World Mental Health Composite International Diagnostic Interview, version 2.1, to identify likely diagnoses of an MDE, GAD, and panic disorder. This valid, reliable, and fully structured lay interview 27 has been administered to more than 150 000 people from 28 countries, including pregnant women. 28, 29 It is reliable when administered via the telephone. 30 We required a minimum of 1 month, rather than 6 months, of symptoms to meet the criteria for GAD in pregnancy since the interval of follow-up was short. Previous work showed that this duration is associated with substantial functional impairment. 31 We excluded a diagnosis of panic disorder if women had a medical condition that could account for panic attacks (eg, asthma attacks). We assessed PTSD with a module from the Mini-International Neuropsychiatric Interview. 32 All women were administered the Edinburgh Postnatal Depression Scale (EPDS), 33 which includes an anxiety subscale.
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Pregnancy dating used an algorithm that prioritized ultrasonography results prior to 18 weeks and, if unavailable, used the last menstrual period. A birth was designated as preterm if it occurred before 36 completed weeks of gestation (36 weeks and 6 days). Birth weight and delivery mode were abstracted from the medical record. Low-birth-weight deliveries were designated as those less than 2500 g. Hypertensive diseases of pregnancy were operationalized as incident hypertension after 20 weeks of pregnancy (and after exposure to illness or medication for those exposed) or preeclampsia as designated in the medical record. Minor neonatal respiratory interventions included delee suction or tracheal suction and oxygen administration; ventilatory support included use of a ventilator or continuous positive airway pressure.
Potential Confounding Variables
At the home interview, we obtained information about height, participant-reported race/ethnicity, prepregnancy weight, and preceding pregnancy outcomes as well current medical complications, such as asthma, hyperemesis, hyperthyroidism, and preexisting hypertension and use of any substances or prescribed medications. This information was obtained at each follow-up interview. After delivery, data on maternal illnesses in pregnancy were also abstracted from medical records.
Possible confounding variables were operationalized as follows: heavy alcohol use was defined as 4 or more drinks per week or 3 or more drinks in 1 sitting any time in pregnancy; illicit substance use as any use in pregnancy; previous pregnancy outcomes were coded as a 2-level categorical variable (previous preterm birth vs term births only or no previous live births); age was categorized (<25, 25-34, and ≥35 years); race/ ethnicity included Hispanic, black, white, and other; educational level was categorized (<12, 12, 13-15, and ≥16 years) ; and body mass index was calculated as weight in kilograms divided by height in meters squared.
Statistical Analysis
We adopted several conventions for missing data. If a woman met criteria for a psychiatric diagnosis at any point in pregnancy, she was classified as positive for that disorder. If a woman had partial data (eg, missed 1 or 2 interviews) and was negative for a disorder, we considered her negative for that disorder during pregnancy. We also conducted a sensitivity analysis using complete cases. Rates of missing data by visit are in the Figure. To estimate associations between exposures and outcomes, we used logistic regression and built separate unadjusted and adjusted models for each outcome. All adjusted models included main exposures (panic disorder, GAD, benzodiazepine use, and SRI use) and possible confounders (age, race/ethnicity, and educational level, as well as smoking, heavy drinking, illicit drug use, MDE, and PTSD during pregnancy, plus the interaction of MDE with panic disorder, GAD, or PTSD). Body mass index was included as an explanatory variable in models for all outcomes except neonatal ventilatory support and minor neonatal respiratory interventions. When modeling preterm birth and low birth weight, we adjusted for previous preterm birth. For the cesarean delivery outcome, previous cesarean delivery was included as an explanatory variable. For all models, the interaction between illness (panic disorder, GAD, and MDE) and SRI or benzodiazepine use, as well as between SRI and benzodiazepine use, was tested to determine moderating effects of illness or medication. Adjusted risk differences were calculated using the modified ordinary least squares method by Cheung. 35 We used SAS, version 9.4 (SAS Institute Inc) for analyses. P < .05 (2-sided) was considered significant.
Results
Study Enrollment
We screened 9525 women and invited 3517 to participate (women with an MDE in the past 5 years, with PTSD, or undergoing SRI treatment, as well as randomly selected nonexposed participants). In this secondary analysis, exposure groups were recoded to include panic disorder, GAD, SRI use, or benzodiazepine treatment. Of the women invited to participate, 2793 underwent at least a home interview. This analysis includes 2654 singleton live births. 7 Data on birth outcomes were available for 2634 of the 2654 singleton births (99.2%). A figure for participant flow is provided in a previous publication 26 and the the eFigure in the Supplement.
Exposure Rates
The Figure shows More women used SRIs during the first (n = 257) compared with the second (n = 157) and third (n = 147) trimesters.
Participant Characteristics
Participant characteristics by exposure group are in 
Associations With Exposures
Unadjusted and adjusted models are presented in Table 2 and Table 3 . No interactions between benzodiazepine or SRI use were significant. Adjusted models showed no significant associations between panic disorder or GAD and maternal or neonatal complications of interest. The co-occurrence of either panic disorder or GAD with an MDE did not increase the risk of these outcomes.
Exposure to a benzodiazepine resulted in the following associations in adjusted models independent of panic disorder, GAD, and SRI use: risk of cesarean delivery (odds ratio [OR] We reran these analyses using complete cases and found similar significant associations. However, the association between panic disorder and neonatal ventilatory support became significant, and the association between benzodiazepine use and this outcome lost significance.
To better understand the correlation between benzodiazepine use and fetal growth, we conducted a post hoc logistic regression analysis adjusted for all covariates and used delivery of small for gestational age infant as the outcome (this outcome considers size for birth age rather than low birth weight at any age). The association was not significant (OR, 0.85; 95% CI, 0.35-2.10). Similarly, because benzodiazepine use in pregnancy was marginally associated with preterm birth (OR, 1.98; 95% CI, 0.97-4.04), we used a multiple linear regression model to test the difference in mean duration of gestation in days between those using and not using benzodiazepines adjusted for the same potential confounders included in the preterm birth model. Exposure to benzodiazepines shortened gestational duration by 3.6 days (β = -3.6, SE = 1.7; P = .03).
Use of an SRI was associated with preterm birth (OR, 1.56; 95% CI, 1.02-2.38) ( Table 2) as previously reported, 7 as well as the need for minor neonatal respiratory interventions (OR, 1.81; 95% CI, 1.39-2.37) ( Table 3 ). In addition, SRI exposure was associated with hypertensive diseases of pregnancy (OR, 2.82; 95% CI, 1.58-5.04) ( Table 2 ). Gestation was 1.8 days shorter in women who received SRIs during pregnancy compared with those who did not. Estimated probabilities were 43 additional preterm births per 1000 births (95% CI, 35-51), 152 additional newborns needing minor respiratory interventions per 1000 births (95% CI, 47-158), and 53 additional cases of maternal hypertension per 1000 births (95% CI, 46-60). Sensitivity analyses that added the anxiety subscale of the EDPS were consistent with the models presented above.
Discussion
In this carefully characterized cohort of women who were longitudinally followed up through pregnancy, neither maternal panic disorder nor GAD was associated with the maternal or neonatal pregnancy complications of interest. Maternal use of a benzodiazepine was associated with delivery of a low-birth-weight infant, cesarean delivery, and neonatal ventilatory support. Use of an SRI was associated with preterm birth, minor neonatal respiratory interventions, and hypertensive diseases of pregnancy. To our knowledge, few reports focus specifically on anxiety disorders and birth outcomes.
3-5 Our results differ from those that showed an association between panic disorder and preterm ; reliance on registry data for referenced studies, which can be inaccurate compared with systematic diagnostic interviews, may be a factor. Indeed, panic attacks can occur in patients with several psychiatric conditions, including PTSD. A previous study showed a robust association between preterm birth and comorbid PTSD and an MDE, 26 which is reflected in the present analyses. However, with only 98 participants who met the criteria for panic disorder, we may have had limited power to find an association. The limits of power are exacerbated by the need to control for other possible confounders. The postadjustment changes in ORs, particularly for maternal outcomes among those with panic disorder, were substantial. This finding reflects the difficulty of determining the offending exposure when comorbidity among the various psychiatric disorders is frequent. We Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); GAD, generalized anxiety disorder; MDE, major depressive episode; PTSD, posttraumatic stress disorder; SRI, serotonin reuptake inhibitor.
a Hypertension that began after 20 weeks of pregnancy and after exposure to illness or medication and included preeclampsia; 20 women were excluded for unknown maternal hypertension status.
b A total of 16 women were excluded for unknown delivery method.
c Less than 37 weeks' gestation.
d Less than 2500 g; 2 women were excluded for unknown birth weight.
e Use of a ventilator or continuous positive airway pressure; 16 infants were excluded for unknown neonatal outcomes.
f Tracheal suction, intubation, or oxygen administration; 16 infants were excluded for unknown neonatal outcomes and 1 infant was excluded for fetal demise.
g Percentages may not total 100% owing to rounding.
h Heavy drinking defined as more than 2 drinks on any given day or more than 3 drinks per week.
i A total of 13 women were missing BMI data. diagnosed 252 women as having GAD, but we shortened the required symptomatic period from 6 months to 1 month, and women may have been mildly afflicted in this length of time. Prior work has found that case status is not substantially different for GAD that endures 1 vs 6 months.
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The literature on benzodiazepine use in pregnancy is dominated by reports on the risk of fetal malformations. However, some work 25, 37 has found that neonates exposed to benzodiazepines in utero are more likely to have respiratory difficulties, particularly if exposure is late in gestation. This finding aligns with our finding of increased need for ventilatory support among neonates exposed to benzodiazepines, although it was uncommon. Several reports show an association between preterm birth and benzodiazepine treatment in pregnancy 22, 23, 38 although there are inconsistencies. 39 Calderon-Margalit et al 22 reported
that the risk of preterm birth is greater if women were treated later rather than earlier in pregnancy. Women in our cohort had predominantly early exposures to benzodiazepines, and the duration of gestation was shortened by only 3.6 days.
Confounding by indication may explain the linkage in other studies between late benzodiazepine use and the risk of preterm birth. Women who had pregnancy complications may have been prescribed benzodiazepines for anxiety related to obstetrical risks. Alternatively, benzodiazepine treatment proximal to delivery may be more problematic than early treatment in terms of the risk of preterm delivery. γ-Amino butyric acid agonists can trigger apoptosis, 40 which could theoretically weaken fetal membranes, but the finding of apoptosis was in the central nervous system and it is not clear whether this finding extends to fetal membranes. Other studies have found that maternal benzodiazepine use is linked with delivery of a low-birth-weight infant, 22,25 but these investigations showed that the infants were appropriately sized for gestational age. The associations we found for SRI use in pregnancy (risk of preterm birth, minor neonatal respiratory interventions, and hypertension diseases of pregnancy) have also been reported by others. 8, 17, 18, [41] [42] [43] We found that the absolute difference in the duration of gestation among women who were or were not treated with an SRI was only 1.8 days.
Several maternal and neonatal outcomes can be influenced by illness severity and unmeasured confounding factors. An earlier report investigated the role of illness severity (early onset of depression, hospitalization, and suicidal ideation) on the risk of preterm birth among women treated with SRIs in pregnancy. 7 The association was attenuated only slightly. As shown in eTable 2 in the Supplement, the mean EPDS score was not higher for women treated with SRIs in preg- nancy than for those who were not; a sensitivity analysis that included the EPDS anxiety subscale did not change the significance of our findings, suggesting that illness severity did not confound associations with this exposure.
Strengths and Limitations
Our study is one of a few that evaluated the possible association of common anxiety disorders with maternal and neonatal risk of hypertensive diseases of pregnancy, cesarean delivery, preterm birth, low birth weight, neonatal ventiliatory support, and minor neonatal respiratory intervention. Our data collection was longitudinal and prospective and relied on structured interviews to assign likely psychiatric diagnoses. It is the only study to our knowledge that evaluated the effects of benzodiazepines and SRIs independently from the anxiety disorder. An additional strength was inclusion of information about other potential confounders, such as licit and illicit substance use. Limitations include administration of structured interviews by trained lay interviewers and reliance on self-report for substance use; medical record data provide some accuracy compared with self-report, but important information may not be included in the record. In addition, there were too few women taking medication to determine dosages that might be problematic. It is reassuring that there were no adverse maternal and neonatal outcomes directly associated with illness. The use of medication shortened gestation by only a small amount, and we saw no association between medication use and fetal growth. Respiratory effects in neonates appeared to be more severe in neonates exposed to benzodiazepines than those exposed to SRIs.
Conclusions
In general, women are reluctant to take medication in pregnancy, and medication exposures are typically the result of necessity. Often, mothers have the clearest sense of their risk of relapse if medication is discontinued, and this relapse bears on her wellbeing and that of her offspring. In addition, treatment may be necessary for the mother to carry the pregnancy to term. 44 Clinicians and patients need to consider both maternal illness and treatment needs in addition to risks associated with offspring when making treatment decisions in pregnancy. Author Contributions: Dr Yonkers and Ms GilstadHayden had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. (74) 59 (60) 1898 (74) 172 (68) 1785 (74) Hispanic 383 (14) 20 (20) 363 (14) 37 (15) 346 (14) Black 195 (7) 17 (17) 178 (7) 36 (14) 159 (7 172 (6) 15 (15) 157 (6) 25 (10) 147 (6) 12 382 (14) 21 (21) 361 (14) 39 (15) 343 (14) 13-15 599 (23) 28 (29) 571 (22) 78 (31) 521 (22) 16+ 1501 (57) 34 (35) 1467 (57) 110 (44) 1391 (58) Anxiety subscale of EPDS, possible range of scores is from 0 to 9, with higher scores indicating more severe symptoms LCL= lower confidence limit; UCL= upper confidence limit; NHH= number needed to harm
